- Home
- KWR vs ARQT Comparison
KWR vs ARQT Comparison
Compare KWR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWR
- ARQT
- Stock Information
- Founded
- KWR 1918
- ARQT 2016
- Country
- KWR United States
- ARQT United States
- Employees
- KWR N/A
- ARQT N/A
- Industry
- KWR Major Chemicals
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- KWR Industrials
- ARQT Health Care
- Exchange
- KWR Nasdaq
- ARQT Nasdaq
- Market Cap
- KWR 1.8B
- ARQT 1.5B
- IPO Year
- KWR 1985
- ARQT 2020
- Fundamental
- Price
- KWR $104.93
- ARQT $14.72
- Analyst Decision
- KWR Strong Buy
- ARQT Strong Buy
- Analyst Count
- KWR 4
- ARQT 6
- Target Price
- KWR $157.75
- ARQT $18.80
- AVG Volume (30 Days)
- KWR 197.2K
- ARQT 2.5M
- Earning Date
- KWR 05-01-2025
- ARQT 05-06-2025
- Dividend Yield
- KWR 1.88%
- ARQT N/A
- EPS Growth
- KWR 3.95
- ARQT N/A
- EPS
- KWR 6.51
- ARQT N/A
- Revenue
- KWR $1,839,686,000.00
- ARQT $196,542,000.00
- Revenue This Year
- KWR $2.57
- ARQT $60.21
- Revenue Next Year
- KWR $4.77
- ARQT $40.21
- P/E Ratio
- KWR $15.82
- ARQT N/A
- Revenue Growth
- KWR N/A
- ARQT 229.74
- 52 Week Low
- KWR $95.91
- ARQT $6.99
- 52 Week High
- KWR $197.03
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- KWR 37.88
- ARQT 53.42
- Support Level
- KWR $98.26
- ARQT $12.51
- Resistance Level
- KWR $109.26
- ARQT $15.02
- Average True Range (ATR)
- KWR 6.03
- ARQT 1.21
- MACD
- KWR 0.50
- ARQT 0.04
- Stochastic Oscillator
- KWR 50.03
- ARQT 70.33
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.